LIVE WEBINAR: Tuesday, August 9, 2022, 5:00 PM – 6:30 PM Eastern Time (ET)

Data + Perspectives: Investigators Discuss the Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies in the Care of Patients with Hematologic Cancers

A CE/NCPD-Accredited Virtual Event in Partnership with the 2022 Pan Pacific Lymphoma Conference

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.


Join us on Tuesday, August 9th for this CE/NCPD-accredited webinar
5:00 PM – 6:30 PM ET

Faculty
Ajai Chari, MD
Professor of Medicine (Hematology and Medical Oncology)
Icahn School of Medicine at Mount Sinai
Director, Clinical Research
Multiple Myeloma Program
Associate Medical Director
The Tisch Cancer Institute Clinical Trials Office
New York, New York

Ian W Flinn, MD, PhD
Director of Lymphoma Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Nikhil C Munshi, MD
Kraft Family Chair
Director of Basic and Correlative Science
Jerome Lipper Multiple Myeloma Center
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Laurie H Sehn, MD, MPH
Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
University of British Columbia
Associate Editor, Blood
Vancouver, British Columbia, Canada

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from Genentech, a member of the Roche Group, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Tuesday, August 9, 2022
5:00 PM – 6:30 PM Eastern Time
Live CE/NCPD-accredited webinar

Topics to Be Discussed

  • Module 1: Current and Emerging Roles of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Aggressive and Indolent Lymphomas
  • MODULE 2: Biologic Rationale for, Available Data with and Potential Clinical Use of CD20 x CD3 Bispecific Antibodies for Lymphoma
  • MODULE 3: Optimal Integration of BCMA-Directed CAR T-Cell Therapy into the Care of Patients with Multiple Myeloma (MM)
  • MODULE 4: BCMA and Non-BCMA Bispecific Antibodies Under Investigation for MM

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows, pathologists, nurse practitioners, clinical nurse specialists, pharmacists and other healthcare providers involved in the treatment of hematologic cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Develop an understanding of the scientific rationale for the development of chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells, and appreciate the similarities and differences between commercially available and investigational products.
  • Appraise existing efficacy data from clinical trials of approved CAR T-cell therapies directed at CD19 for relapsed/refractory B-cell lymphomas, and use this information to identify patients who may be candidates for this approach.
  • Appreciate available data documenting the activity of CAR T-cell therapy targeting BCMA in multiple myeloma (MM), and use this knowledge to counsel patients who may be appropriate for this approach within or outside of a protocol setting.
  • Evaluate the mechanism of action of and available clinical trial findings with bispecific antibodies targeting CD20 and CD3 in patients with B-cell lymphomas.
  • Review the biologic rationale for and available efficacy findings with BCMA- and non-BCMA-directed bispecific antibodies for MM, and consider the potential clinical role of these agents.
  • Recognize common adverse events associated with approved and investigational CAR T-cell therapies and bispecific T-cell-engaging antibodies, and implement strategies to educate patients who are eligible for these treatments about the potential for complications.
  • Recall ongoing research evaluating bispecific antibodies or CAR T-cell-based approaches for various B-cell lymphomas, chronic lymphocytic leukemia and MM, and counsel appropriate patients regarding the potential benefits of trial participation.

Accreditation Statement
In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS: The University of Nebraska Medical Center designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES: The University of Nebraska Medical Center designates this activity for 1.5 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

Credit Form
A credit form link will be emailed to each participant within 3 business days of this activity.

All credit certificates will be issued to attendees by UNMC CCE within 4 to 6 weeks after the live webcast.

Disclosure Information
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.

All faculty, planners, and others in a position to control continuing education content participating in a UNMC-accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

Disclosures
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:

FACULTYDr Munshi has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr ChariAdvisory Committee: Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Sanofi Genzyme, Seagen Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Takeda Pharmaceuticals USA Inc; Contracted Research: Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Oncoceutics Inc, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Takeda Pharmaceuticals USA Inc. Dr FlinnConsulting Agreements (to Sarah Cannon Research Institute): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Century Therapeutics, Genentech, a member of the Roche Group, Genmab, Hutchison MediPharma, Iksuda Therapeutics, InnoCare Pharma, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Myeloid Therapeutics, Novartis, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Secura Bio, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Verastem Inc, Vincerx Pharma, Xencor; Research Grants (to Sarah Cannon Research Institute): 2seventy bio, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Agios Pharmaceuticals Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bio-Path Holdings Inc, Bristol-Myers Squibb Company, CALGB, Calibr, Celgene Corporation, City of Hope National Medical Center, Constellation Pharmaceuticals, CTI BioPharma Corp, Curis Inc, Epizyme Inc, Fate Therapeutics, FORMA Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IGM Biosciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, InnoCare Pharma, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MorphoSys, Myeloid Therapeutics, Novartis, Nurix Therapeutics Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, Rhizen Pharmaceuticals AG, Roche Laboratories Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc, TCR2 Therapeutics, Tessa Therapeutics, TG Therapeutics Inc, Trillium Therapeutics Inc, Triphase Research and Development Corporation, Unum Therapeutics, Verastem Inc. Dr SehnConsulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Seagen Inc, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Contracted Research: Genentech, a member of the Roche Group, Teva Oncology.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

THE UNIVERSITY OF NEBRASKA MEDICAL CENTER (UNMC) and RESEARCH TO PRACTICE (RTP) PLANNERS, STAFF AND REVIEWERS — The below planning committee members have nothing to disclose: Neil Love, MD — RTP President and Planner, Atif Hussein, MD — RTP Reviewer, Renee Paulin, MSN, RN, CWOCN — UNMC Planner and Reviewer, Brenda Ram, CMP, CHCP — UNMC Planner, Michele Williams, DNP, AGPCNP-BC — RTP Reviewer, and Kathryn Ault Ziel, PhD — RTP Staff and Planner.

Supporters
This activity is supported by educational grants from Genentech, a member of the Roche Group, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.